文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

神经外科重症监护病房患者脑脊液万古霉素浓度监测及其影响因素分析

[Therapeutic monitoring of cerebrospinal fluid vancomycin concentrations and analysis of their influencing factors in neurosurgical intensive care unit patients].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2019-01-01
一句话结论神经外科重症患者单用静脉万古霉素难以达到脑脊液目标浓度,局部给药可有效提高脑脊液万古霉素浓度。

该回顾性研究纳入2016年1月至2019年6月中山大学附属第一医院神经外科ICU收治的22例接受万古霉素治疗并监测脑脊液万古霉素浓度的成年患者,共获取60例次脑脊液万古霉素浓度。脑脊液万古霉素浓度范围为<0.24至>100 mg/L,平均14.40(4.79,42.34)mg/L。鞘内注射或脑室内给药者脑脊液万古霉素浓度高于单用静脉给药者[25.91(11.28,58.17)mg/L vs. 2.71(0.54,5.33)mg/L,P<0.01]。局部给药剂量0-15 mg组、20-35 mg组和40-50 mg组脑脊液万古霉素浓度分别为4.14(1.09,8.45)、30.52(14.31,59.61)和59.43(25.51,92.45)mg/L,差异有统计学意义(P<0.01);局部给药剂量≥20 mg时脑脊液万古霉素浓度多能达到目标水平。

要点

  • 神经外科ICU患者单用静脉万古霉素时,确诊和不确定中枢神经系统感染组的脑脊液万古霉素浓度分别为4.14(1.40,6.36)mg/L和1.27(0.24,3.33)mg/L,均较低且无显著差异(P=0.086)。
  • 鞘内注射或脑室内给药者脑脊液万古霉素浓度为25.91(11.28,58.17)mg/L,高于单用静脉给药者的2.71(0.54,5.33)mg/L(P<0.01)。
  • 局部给药剂量0-15 mg组、20-35 mg组、40-50 mg组的脑脊液万古霉素浓度分别为4.14(1.09,8.45)、30.52(14.31,59.61)、59.43(25.51,92.45)mg/L,随剂量增加而升高(P<0.01)。
  • 局部给药剂量0-15 mg组、20-35 mg组、40-50 mg组脑脊液万古霉素浓度≥10 mg/L的病例分别占18.2%、84.8%和100%。
  • 局部给药剂量≥20 mg时脑脊液万古霉素浓度多能达到目标水平。

适用人群与场景

  • 2016年1月至2019年6月中山大学附属第一医院神经外科ICU收治的成年患者,接受万古霉素治疗并监测脑脊液万古霉素浓度。

诊断标准与关键阈值

  • 中枢神经系统感染诊断分为确诊(proven)、临床诊断(probable)、不确定(possible)和无感染(non-infection);确诊+临床诊断为确定中枢神经系统感染,不确定+无感染为不确定中枢神经系统感染。
  • 脑脊液万古霉素浓度目标水平为≥10 mg/L(原文以该阈值分组报告达标比例)。

处置流程与药物剂量

  • 给药方式包括单用静脉给药、鞘内注射、静脉+鞘内注射、静脉+脑室内给药。
  • 局部给药(鞘内注射或脑室内给药)剂量分组:0-15 mg组(n=22)、20-35 mg组(n=33)、40-50 mg组(n=5),按治疗药物监测前一日局部给药剂量分组。
  • 局部给药剂量≥20 mg时脑脊液万古霉素浓度多能达到目标水平。

研究设计与关键结果

  • 回顾性研究,纳入22例患者,获取60例次脑脊液万古霉素浓度;168份脑脊液标本培养阳性20份,阳性率11.9%。
  • 22例中确诊中枢神经系统感染7例(31.8%),临床诊断11例(50.0%),不确定2例(9.1%),无感染2例(9.1%)。
  • 给药方式:单用静脉给药15例(25.0%),鞘内注射17例(28.3%),静脉+鞘内注射23例(38.3%),静脉+脑室内给药5例(8.3%)。
  • 脑脊液万古霉素浓度范围为<0.24至>100 mg/L,平均14.40(4.79,42.34)mg/L。
  • 鞘内注射或脑室内给药者脑脊液万古霉素浓度高于单用静脉给药者[25.91(11.28,58.17)mg/L vs. 2.71(0.54,5.33)mg/L,U=42.000,P<0.01]。
  • 单用静脉给药时,确定中枢神经系统感染组与不确定中枢神经系统感染组的脑脊液万古霉素浓度分别为4.14(1.40,6.36)mg/L和1.27(0.24,3.33)mg/L,无显著差异(U=11.000,P=0.086)。
  • 局部给药剂量0-15 mg组、20-35 mg组、40-50 mg组脑脊液万古霉素浓度分别为4.14(1.09,8.45)、30.52(14.31,59.61)、59.43(25.51,92.45)mg/L,差异有统计学意义(H=33.399,P<0.01);三组脑脊液万古霉素浓度≥10 mg/L的病例分别占18.2%、84.8%和100%。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于神经外科重症患者,无论是否合并中枢神经系统感染,单用静脉万古霉素难以达到脑脊液目标浓度。
  • 作者认为,局部给药是提高脑脊液万古霉素浓度的有效治疗方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate cerebrospinal fluid (CSF) vancomycin concentrations and identify factors influencing CSF vancomycin concentrations in critically ill neurosurgical patients.

METHODS: A retrospective study was conducted. Adult patients who received vancomycin treatment and CSF vancomycin concentrations monitoring admitted to neurosurgical intensive care unit (ICU) of the First Affiliated Hospital of Sun Yat-sen University from January 2016 to June 2019 were enrolled. General information, vancomycin dosing regimens, CSF vancomycin concentrations, CSF drainage methods and volume of the previous day, and concurrent medications, etc. were collected for analysis. CSF vancomycin concentrations of patients with definite or indefinite central nervous system (CNS) infection, different vancomycin dosing regimens and their influencing factors were analyzed.

RESULTS: A total of 22 patients were included. 168 CSF specimens were collected for culture, 20 specimens of which were culture positive, with a positive rate of 11.9%. Sixty cases of CSF vancomycin concentration were obtained. Among the 22 patients, 7 patients (31.8%) were diagnosed with proven CNS infection, 11 patients (50.0%) clinically diagnosed, 2 patients (9.1%) diagnosed with uncertain CNS infection, and 2 patients (9.1%) diagnosed without CNS infection. Intravenous (IV) administration of vancomycin alone was used in 15 cases (25.0%), intrathecal injection in 17 cases (28.3%), IV+intrathecal injection in 23 cases (38.3%), and IV+intraventricular administration in 5 cases (8.3%). The CSF vancomycin concentrations ranged from < 0.24 to > 100 mg/L, with an average level of 14.40 (4.79, 42.34) mg/L. (1) Administration methods of vancomycin affected CSF vancomycin concentrations. The CSF vancomycin concentration with intrathecal injection or intraventricular administration was higher than that of IV administration alone [mg/L: 25.91 (11.28, 58.17) vs. 2.71 (0.54, 5.33), U = 42.000, P < 0.01]. (2) When vancomycin was administered by IV treatment alone, CSF vancomycin concentrations were low in both groups with definite CNS infection (proven+probable) and indefinite CNS infection (possible+non-infection), the CSF vancomycin concentrations of which were 4.14 (1.40, 6.36) mg/L and 1.27 (0.24, 3.33) mg/L respectively, with no significant difference (U = 11.000, P = 0.086). (3) CSF vancomycin concentrations rose with the increased dose of vancomycin delivered by intrathecal injection or intraventricular administration. According to the dose of vancomycin administered locally on the day before therapeutic drug monitoring (TDM), cases were divided into the following groups: 0-15 mg group (n = 22), 20-35 mg group (n = 33), and 40-50 mg group (n = 5), the CSF vancomycin concentrations of which were 4.14 (1.09, 8.45), 30.52 (14.31, 59.61) and 59.43 (25.51, 92.45) mg/L respectively, with significant difference (H = 33.399, P < 0.01). Moreover, the cases of CSF vancomycin concentration of ≥ 10 mg/L accounted for 18.2%, 84.8% and 100% of these three groups, respectively. CSF vancomycin concentrations mostly reached target level when dose of vancomycin administered locally were 20 mg/L or more.

CONCLUSIONS: It is difficult to reach target CSF vancomycin concentration for critically ill neurosurgical patients with or without CNS infection by IV treatment. Local administration is an effective treatment regimen to increase CSF vancomycin concentration.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yao M, Li J, Shi L, et al. [Therapeutic monitoring of cerebrospinal fluid vancomycin concentrations and analysis of their influencing factors in neurosurgical intensive care unit patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31771724. doi:10.3760/cma.j.issn.2095-4352.2019.10.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。